HEAL

HEAL remains in a Stage 2 advancing regime with clear higher highs and higher lows supported by rising EMAs and the 50 DMA. The recent Bullish Exhaustion pattern indicates waning upside momentum, but the pullback is resolving as corrective and holding at the 9/21 EMA zone. Neutral overbought/oversold context and favorable volume dynamics support measured entries, making buying the dip into rising EMAs aligned with medium-term structure and momentum.

• ↑HEAL AUM ~$30.4M provides diversified exposure to health tech innovators
• ↑Top holdings like IQVIA and DexCom support robust revenue growth
• ↓YTD NAV down 9.4% underscores recent underperformance